They dumped Galapagos because they are seeing good results with their in-house jak1 investigational drug.
It's on the NVAX website .
Most institutions won't or can't buy pink sheet stocks. That's why uplisting is so important.
I think the short half life in infants is a disappointment. Also they don't say how antibody level compares with Synagis antibody level.